Targeting ATR signaling in sarcoma with homologous recombination deficiency
RNA-seq (gene expression) · human · 68 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Soft tissue sarcomaThis series is part of our curated briefing on it.
- Samples
- 68 samples: 5 conditions, mostly with about 12 replicates eachGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE299349_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1273954 and SRA study SRP590928. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 62 samples.
How we read this: 5 replicated groups read from 68 sample titles; they account for 62 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9037835 USZ-20_REA1
- GSM9037836 USZ-21_LG1
- GSM9037837 USZ-23_EMC3
- GSM9037838 USZ-21_UPS1
- GSM9037839 USZ-21_MFS2
- GSM9037840 NMFH1
- GSM9037841 MFS01 MFS
- GSM9037842 MFS02 MFS
- GSM9037843 MFS03 MFS
- GSM9037844 MFS04 MFS
- GSM9037845 MFS05 MFS
- GSM9037846 MFS06 MFS
- GSM9037847 MFS07 MFS
- GSM9037848 MFS08 MFS
- GSM9037849 MFS09 MFS
- GSM9037850 MFS10 MFS
- GSM9037851 MFS11 MFS
- GSM9037852 MFS12 MFS
- GSM9037853 MFS13 MFS
- GSM9037854 MFS14 MFS
- GSM9037855 SS01 SS
- GSM9037856 SS02 SS
- GSM9037857 SS03 SS
- GSM9037858 SS04 SS
- GSM9037859 SS05 SS
- GSM9037860 SS06 SS
- GSM9037861 SS07 SS
- GSM9037862 SS08 SS
- GSM9037863 SS09 SS
- GSM9037864 SS10 SS
- GSM9037865 SS11 SS
- GSM9037866 SS12 SS
- GSM9037867 UPS01 UPS
- GSM9037868 UPS02 UPS
- GSM9037869 UPS03 UPS
- GSM9037870 UPS04 UPS
- GSM9037871 UPS05 UPS
- GSM9037872 UPS06 UPS
- GSM9037873 UPS07 UPS
- GSM9037874 UPS08 UPS
+ 28 more — browse all 68 samples with per-sample file links →
- GSE314949 RNA Seq of rhabdomyosarcoma cells with sgRNA targeting oncofusion interacting proteins 30 samples same disease briefing · shares targeting, sarcoma
- GSE275734 A multitargeting approach rewires cell identity in fusion-negative rhabdomyosarcoma [Human_RNAseq_bulk] 8 samples same disease briefing · shares targeting, sarcoma
- GSE279213 Targeting De Novo Cholesterol Synthesis as a Therapeutic Strategy in Rhabdomyosarcoma 8 samples same disease briefing · shares targeting, sarcoma
- GSE332748 PAX3::FOXO1-Targeting PROTAC Induces Myogenic Differentiation of Fusion-Positive Rhabdomyosarcoma Cells 6 samples same disease briefing · shares targeting, sarcoma
- GSE276201 A multitargeting approach rewires cell identity in fusion-negative rhabdomyosarcoma 28 samples same disease briefing · shares targeting, sarcoma
- GSE275736 A multitargeting approach rewires cell identity in fusion-negative rhabdomyosarcoma [bulk_ATACseq] 8 samples same disease briefing · shares targeting, sarcoma
- GSE282611 A multitargeting approach rewires cell identity in fusion-negative rhabdomyosarcoma [snRNAseq and scATACseq] 4 samples same disease briefing · shares targeting, sarcoma
- GSE313525 TAK1 is a key regulator of oncogenic signaling and differentiation blockade in rhabdomyosarcoma 6 samples same disease briefing · shares sarcoma
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.